Biogen Appoints Catherine Steele Senior Vice President of Corporate Affairs
Biogen (NASDAQ: BIIB) announced today the appointment of Catherine Steele as Senior Vice President of Corporate Affairs, effective July 17.
Ms. Steele, who brings more than 25 years of public affairs experience to Biogen, will lead the company’s corporate, product, and internal communications as well government affairs and patient advocacy efforts.
“Catherine is joining us at an exciting time in the evolution of Biogen,” said Chief Executive Officer Michel Vounatsos. “As we strengthen our pipeline, reaffirm our commitment to neuroscience and look to enter new therapeutic areas and markets globally, Catherine will play a crucial role in helping align our business with key public and patient audiences and establish Biogen with new stakeholders globally.”
Ms. Steele most recently served as Global Head, Communications and Patient Relations at Novartis Pharmaceuticals, where she was responsible for corporate reputation and helping drive external, internal and executive communication strategies. She also led the company’s social media and patient relations activities. Her career in the biopharma industry began at Roche, where she spent more than a decade in global communications and policy leadership roles.
"I am privileged to join Biogen, a respected and recognized pioneer in neuroscience," said Ms. Steele. "I look forward to building upon that legacy and being part of this company whose commitment to patients, families and society affected by neurological diseases is unwavering."
Ms. Steele holds dual undergraduate degrees in French and political science from the University of New Brunswick and a Master of Arts degree in political science from Carleton University.
Through cutting-edge science and medicine, Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases. Founded in 1978, Biogen is a pioneer in biotechnology, and today the company has the leading portfolio of medicines to treat multiple sclerosis; has introduced the first and only approved treatment for spinal muscular atrophy; and is at the forefront of neurology research for conditions including Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis. Biogen also manufactures and commercializes biosimilars of advanced biologics. For more information, please visit www.biogen.com . Follow us on social media – Twitter , LinkedIn , Facebook , YouTube .
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Skriv dig op her og modtag pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra Business Wire
DIGI-COMMUNICATIONS-N.V.21.3.2018 20:07 | pressemeddelelse
Digi Communications N.V.: Convocation of the Company’s General Shareholders Meeting for 2 May 2018 for the Approval of, among Others, the 2017 Annual Report and of the 2017 Financial Statements
CA-PANDORA21.3.2018 14:02 | pressemeddelelse
Pandora to Acquire Leading Digital Audio Ad Tech Firm AdsWizz
MYPOS-EUROPE21.3.2018 13:53 | pressemeddelelse
Fintech Entrepreneur and myPOS Founder Christo Georgiev Reveals Plans to Set Up a Chain of myPOS Stores across Europe
AI-EXPO-EUROPE21.3.2018 13:49 | pressemeddelelse
AI Expo Europe: The leading Artificial Intelligence Event to Arrive in the European Capital of Innovation, Amsterdam
PMI21.3.2018 13:34 | pressemeddelelse
Philip Morris International Shifts Entire Capacity of Its Cigarette Factory in Greece to Smoke-Free Products
NY-GSMA21.3.2018 13:02 | pressemeddelelse
GSMA Advances a Comprehensive Agenda on Digital Inclusion for Women Ahead of G20 Summit
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum